Top

Published in:

Open Access 01-12-2024 | Research

Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer

Authors: Tianlei Xie, Shan Peng, Shujun Liu, Minghao Zheng, Wenli Diao, Meng Ding, Yao Fu, Hongqian Guo, Wei Zhao, Junlong Zhuang

Published in: Molecular Cancer | Issue 1/2024

Abstract

Bladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances. While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both operable and advanced bladder cancer, identifying patients who will respond is challenging. Anoikis, a specialized form of cell death that occurs when cells detach from the extracellular matrix, is closely linked to tumor progression. Here, we aimed to explore the anoikis-based biomarkers for bladder cancer prognosis and immunotherapeutic decisions. Through consensus clustering, we categorized patients from the TCGA-BLCA cohort into two clusters based on anoikis-related genes (ARGs). Significant differences in survival outcome, clinical features, tumor immune environment (TIME), and potential ICIs response were observed between clusters. We then formulated a four-gene signature, termed "Ascore", to encapsulate this gene expression pattern. The Ascore was found to be closely associated with survival outcome and served as an independent prognosticator in both the TCGA-BLCA cohort and the IMvigor210 cohort. It also demonstrated superior predictive capacity (AUC = 0.717) for bladder cancer immunotherapy response compared to biomarkers like TMB and PD-L1. Finally, we evaluated Ascore’s independent prognostic performance as a non-invasive biomarker in our clinical cohort (Gulou-Cohort1) using circulating tumor cells detection, achieving an AUC of 0.803. Another clinical cohort (Gulou-Cohort2) consisted of 40 patients undergoing neoadjuvant anti-PD-1 treatment was also examined. Immunohistochemistry of Ascore in these patients revealed its correlation with the pathological response to bladder cancer immunotherapy (P = 0.004). Impressively, Ascore (AUC = 0.913) surpassed PD-L1 (AUC = 0.662) in forecasting immunotherapy response and indicated better net benefit. In conclusion, our study introduces Ascore as a novel, robust prognostic biomarker for bladder cancer, offering a new tool for enhancing immunotherapy decisions and contributing to the tailored treatment approaches in this field.

Available only for authorised users

Compérat E, Amin MB, Cathomas R, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400(10364):1712–21. https://doi.org/10.1016/S0140-6736(22)01188-6.CrossRefPubMed

Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94. https://doi.org/10.1016/j.eururo.2021.08.010.CrossRefPubMed

Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021;79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055.CrossRefPubMed

Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931–45. https://doi.org/10.1016/S1470-2045(21)00152-2.CrossRefPubMed

Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102–14. https://doi.org/10.1056/NEJMoa2034442.CrossRefPubMedPubMedCentral

Meeks JJ, Black PC, Galsky M, et al. Checkpoint Inhibitors in urothelial carcinoma-future directions and biomarker selection. Eur Urol. 2023. https://doi.org/10.1016/j.eururo.2023.05.011.CrossRefPubMed

Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell. 1993;4(9):953–61.CrossRefPubMedPubMedCentral

Sattari Fard F, Jalilzadeh N, Mehdizadeh A, Sajjadian F, Velaei K. Understanding and targeting anoikis in metastasis for cancer therapies. Cell Biol Int. 2022. https://doi.org/10.1002/cbin.11970.CrossRefPubMed

Eckhardt BL, Cao Y, Redfern AD, et al. Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Res. 2020;80(6):1304–15. https://doi.org/10.1158/0008-5472.CAN-19-0743.CrossRefPubMed

10.

Wang J, Luo Z, Lin L, et al. Anoikis-associated lung cancer metastasis: mechanisms and therapies. Cancers (Basel). 2022;14(19):4791. https://doi.org/10.3390/cancers14194791.CrossRefPubMed

11.

Bose M, Sanders A, De C, et al. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Transl Res. 2022. https://doi.org/10.1016/j.trsl.2022.08.010.CrossRefPubMed

12.

Qi L, Chen F, Wang L, Yang Z, Zhang W, Li ZH. Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma. Front Pharmacol. 2023;14:1136184. https://doi.org/10.3389/fphar.2023.1136184.CrossRefPubMedPubMedCentral

13.

Chen Z, Liu X, Zhu Z, et al. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma. Front Genet. 2022;13:1039465. https://doi.org/10.3389/fgene.2022.1039465.CrossRefPubMedPubMedCentral

14.

Yang L, Xu F. A novel anoikis-related risk model predicts prognosis in patients with colorectal cancer and responses to different immunotherapy strategies. J Cancer Res Clin Oncol. 2023;149(12):10879–92. https://doi.org/10.1007/s00432-023-04945-2.CrossRefPubMed

15.

Yue Z, Wang D, Li X. A promising anoikis-related prognostic signature predicts prognosis of skin cutaneous melanoma. J Cancer Res Clin Oncol. 2023;149(20):17757–70. https://doi.org/10.1007/s00432-023-05468-6.CrossRefPubMed

16.

Sun Z, Zhao Y, Wei Y, Ding X, Tan C, Wang C. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma. Front Immunol. 2022;13:939523. https://doi.org/10.3389/fimmu.2022.939523.CrossRefPubMedPubMedCentral

17.

Dong Y, Xu C, Su G, et al. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation. Front Immunol. 2023;14:1122570. https://doi.org/10.3389/fimmu.2023.1122570.CrossRefPubMedPubMedCentral

18.

Zhang YY, Li XW, Li XD, et al. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy. Front Immunol. 2022;13:1055304. https://doi.org/10.3389/fimmu.2022.1055304.CrossRefPubMedPubMedCentral

19.

Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–8. https://doi.org/10.1038/nature25501.CrossRefPubMedPubMedCentral

20.

Sjödahl G, Abrahamsson J, Holmsten K, et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol. 2022;81(5):523–32. https://doi.org/10.1016/j.eururo.2021.10.035.CrossRefPubMed

21.

Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–3. https://doi.org/10.1093/bioinformatics/btq170.CrossRefPubMedPubMedCentral

22.

Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47. https://doi.org/10.1093/nar/gkv007.CrossRefPubMedPubMedCentral

23.

Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.CrossRefPubMedPubMedCentral

24.

Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97. https://doi.org/10.1002/sim.5958.MathSciNetCrossRefPubMed

25.

Chen Z, Zhou L, Liu L, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11(1):5077. https://doi.org/10.1038/s41467-020-18916-5.CrossRefPubMedPubMedCentral

26.

Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587.e29. https://doi.org/10.1016/j.cell.2021.04.048.CrossRefPubMedPubMedCentral

27.

Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.CrossRefPubMed

28.

Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7.CrossRefPubMedPubMedCentral

29.

Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https://doi.org/10.1038/ncomms3612.CrossRefPubMed

30.

Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1.CrossRefPubMedPubMedCentral

31.

Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56. https://doi.org/10.1101/gr.239244.118.CrossRefPubMedPubMedCentral

32.

Hu J, Chen J, Ou Z, et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study. Cell Rep Med. 2022;3(11):100785. https://doi.org/10.1016/j.xcrm.2022.100785.CrossRefPubMedPubMedCentral

33.

Bergmann S, Coym A, Ott L, et al. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). Oncoimmunology. 2020;9(1):1738798. https://doi.org/10.1080/2162402X.2020.1738798.CrossRefPubMedPubMedCentral

34.

Torlakovic EE, Nielsen S, Francis G, et al. Standardization of positive controls in diagnostic immunohistochemistry: recommendations from the International Ad Hoc Expert Committee. Appl Immunohistochem Mol Morphol. 2015;23(1):1–18. https://doi.org/10.1097/pai.0000000000000163.CrossRefPubMed

35.

Torlakovic EE, Francis G, Garratt J, et al. Standardization of negative controls in diagnostic immunohistochemistry: recommendations from the international ad hoc expert panel. Appl Immunohistochem Mol Morphol. 2014;22(4):241–52. https://doi.org/10.1097/pai.0000000000000069.CrossRefPubMedPubMedCentral

36.

Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341–52. https://doi.org/10.1038/s41580-020-0237-9.CrossRefPubMedPubMedCentral

37.

Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–24. https://doi.org/10.1038/nri.2017.142.CrossRefPubMed

38.

Lee Y-C, Lam H-M, Rosser C, Theodorescu D, Parks WC, Chan KS. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol. 2022;19(9):515–33. https://doi.org/10.1038/s41585-022-00608-y.CrossRefPubMedPubMedCentral

39.

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. https://doi.org/10.1038/s41591-018-0014-x.CrossRefPubMedPubMedCentral

40.

Choi E-M, Kwak S-J, Kim Y-M, et al. COX-2 inhibits anoikis by activation of the PI-3K/Akt pathway in human bladder cancer cells. Exp Mol Med. 2005;37(3):199–203.CrossRefPubMed

41.

Lv S, Wang W, Wang H, Zhu Y, Lei C. PPARγ activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway. BMC Cancer. 2019;19(1):204. https://doi.org/10.1186/s12885-019-5426-6.CrossRefPubMedPubMedCentral

42.

Lauss M, Donia M, Harbst K, et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738. https://doi.org/10.1038/s41467-017-01460-0.CrossRefPubMedPubMedCentral

43.

Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237. https://doi.org/10.1016/j.ebiom.2022.104237.CrossRefPubMedPubMedCentral

44.

Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32(11):1136–42. https://doi.org/10.1200/jco.2013.51.7417.CrossRefPubMedPubMedCentral

45.

Wang PP, Liu SH, Chen CT, et al. Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer. J Cancer. 2020;11(8):2113–22. https://doi.org/10.7150/jca.35308.CrossRefPubMedPubMedCentral

46.

Zhang H, Fredericks T, Xiong G, et al. Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance. Breast Cancer Res. 2018;20(1):116. https://doi.org/10.1186/s13058-018-1030-y.CrossRefPubMedPubMedCentral

47.

Burnier JV, Wang N, Michel RP, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene. 2011;30(35):3766–83. https://doi.org/10.1038/onc.2011.89.CrossRefPubMed

48.

Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613–30. https://doi.org/10.1038/s41585-019-0226-y.CrossRefPubMed

49.

Zuo Y, Xu X, Chen M, Qi L. The oncogenic role of the cerebral endothelial cell adhesion molecule (CERCAM) in bladder cancer cells in vitro and in vivo. Cancer Med. 2021;10(13):4437–50. https://doi.org/10.1002/cam4.3955.CrossRefPubMedPubMedCentral

50.

Ahmat Amin MKB, Shimizu A, Ogita H. The pivotal roles of the epithelial membrane protein family in cancer invasiveness and metastasis. Cancers (Basel). 2019;11(11):1620. https://doi.org/10.3390/cancers11111620.CrossRefPubMed

51.

Lin B, Zhang T, Ye X, Yang H. High expression of EMP1 predicts a poor prognosis and correlates with immune infiltrates in bladder urothelial carcinoma. Oncol Lett. 2020;20(3):2840–54. https://doi.org/10.3892/ol.2020.11841.CrossRefPubMedPubMedCentral

52.

Liu S, Shi J, Wang L, et al. Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. Free Radic Biol Med. 2022;189:42–57. https://doi.org/10.1016/j.freeradbiomed.2022.06.247.CrossRefPubMed

53.

Sparrow E, Bodman-Smith MD. Granulysin: The attractive side of a natural born killer. Immunol Lett. 2020;217:126–32. https://doi.org/10.1016/j.imlet.2019.11.005.CrossRefPubMed

54.

Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7(11):833–46.CrossRefPubMed

55.

Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015;7:1–11. https://doi.org/10.15252/emmm.201303698.CrossRefPubMed

56.

Grossmann J. Molecular mechanisms of “detachment-induced apoptosis–Anoikis.” Apoptosis. 2002;7(3):247–60.CrossRefPubMed

57.

Peng T, Wang G, Cheng S, et al. The role and function of PPARγ in bladder cancer. J Cancer. 2020;11(13):3965–75. https://doi.org/10.7150/jca.42663.CrossRefPubMedPubMedCentral

58.

Singh A, Osbourne AS, Koshkin VS. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2023. https://doi.org/10.1007/s11864-023-01113-z.CrossRefPubMed

59.

Anagnostou V, Yarchoan M, Hansen AR, et al. Immuno-oncology trial endpoints: capturing clinically meaningful activity. Clin Cancer Res. 2017;23(17):4959–69. https://doi.org/10.1158/1078-0432.Ccr-16-3065.CrossRefPubMedPubMedCentral

60.

Saal J, Grünwald V, Bald T, et al. On-treatment Modified Glasgow Prognostic Score Provides Predictive Information Complementary to Radiological Staging in Metastatic Urothelial Carcinoma on Immunotherapy. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2023.11.005. Published online November 22 2023.

61.

Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5. https://doi.org/10.1200/jco.2009.25.4599.CrossRefPubMed

Title: Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer
Authors: Tianlei Xie
Shan Peng
Shujun Liu
Minghao Zheng
Wenli Diao
Meng Ding
Yao Fu
Hongqian Guo
Wei Zhao
Junlong Zhuang
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2024
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-024-01945-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application

Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis

Cancer-derived exosomes as novel biomarkers in metastatic gastrointestinal cancer

Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway

Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study

CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p/NUPR1/FTH1 axis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer